| Immune thrombocytopenic purpura
Rhophylac vs Alvaiz
Side-by-side clinical, coverage, and cost comparison for immune thrombocytopenic purpura.Deep comparison between: Rhophylac vs Alvaiz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAlvaiz has a higher rate of injection site reactions vs Rhophylac based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Alvaiz but not Rhophylac, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rhophylac
Alvaiz
At A Glance
IV or IM injection
Single dose
Rh(D) immune globulin
Oral
Daily
TPO-receptor agonist
Indications
- Rh Isoimmunization
- Immune thrombocytopenic purpura
- Immune thrombocytopenic purpura
- Hepatitis C, Chronic
- Severe Aplastic Anemia
Dosing
Rh Isoimmunization 300 mcg (1500 IU) IV or IM injection; routine antepartum prophylaxis at week 28-30 of pregnancy; postpartum and obstetric complication doses within 72 hours of event; for excessive fetomaternal hemorrhage (>15 mL fetal RBCs), 300 mcg plus 20 mcg per mL fetal RBCs in excess of 15 mL; for incompatible transfusions, 20 mcg per 2 mL Rh(D)-positive whole blood within 72 hours of exposure.
Immune thrombocytopenic purpura 50 mcg per kg body weight by IV route only, administered at a rate of 2 mL per 15 to 60 seconds.
Immune thrombocytopenic purpura Initiate at 36 mg orally once daily (18 mg for East-/Southeast-Asian ancestry or hepatic impairment; 9 mg for both); adjust in 18-mg increments to maintain platelet count >=50 x 10^9/L; maximum 54 mg daily.
Hepatitis C, Chronic Initiate at 18 mg orally once daily; adjust in 18-mg increments every 2 weeks to achieve platelet count needed to initiate or maintain pegylated interferon and ribavirin therapy; maximum 72 mg daily; discontinue when antiviral therapy is discontinued.
Severe Aplastic Anemia Initiate at 36 mg orally once daily (18 mg for East-/Southeast-Asian ancestry or hepatic impairment); adjust in 36-mg increments every 2 weeks to maintain platelet count >=50 x 10^9/L; maximum 108 mg daily.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies to IgA and history of hypersensitivity to RHOPHYLAC or any of its components
- Newborn infant of a mother who received RHOPHYLAC postpartum
—
Adverse Reactions
Most common - Rh Isoimmunization (>=0.5%) Nausea, dizziness, headache, injection-site pain, malaise
Most common - Immune thrombocytopenic purpura (>14%) Chills, pyrexia/increased body temperature, increased blood bilirubin, headache
Serious Intravascular hemolysis, clinically compromising anemia, acute renal insufficiency, DIC (observed in ITP treatment)
Postmarketing Hypersensitivity reactions including anaphylactic shock, headache, dizziness, vertigo, hypotension, tachycardia, dyspnea, nausea, vomiting, rash, erythema, pruritus, chills, pyrexia, malaise, diarrhea, back pain
Most common (>=3%) Nausea, diarrhea, upper respiratory tract infection, vomiting, urinary tract infection, increased ALT, myalgia, oropharyngeal pain, increased AST, pharyngitis, back pain, influenza, paresthesia, rash
Serious Hemorrhage, thrombotic/thromboembolic complications, hepatic decompensation, hepatotoxicity, cataracts
Postmarketing Skin discoloration including hyperpigmentation and skin yellowing
Pharmacology
Rh(D) immune globulin (anti-D) that suppresses immunization to Rh(D)-positive RBCs by accelerating their clearance; in ITP, forms Rh(D) immune globulin-RBC complexes preferentially removed by the reticuloendothelial system, causing Fc receptor blockade that spares antibody-coated platelets.
Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (cMpl), initiating signaling cascades that induce proliferation and differentiation of megakaryocytes, leading to increased platelet production.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rhophylac
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (10/12)
Alvaiz
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (1/12)
UnitedHealthcare
Rhophylac
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Alvaiz
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Rhophylac
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Alvaiz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Thrombocytopenia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availablePAF Co-Pay Relief: Aplastic Anemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RhophylacView full Rhophylac profile
AlvaizView full Alvaiz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.